Sanofi SA reported sales of €36 billion for 2019, up by 4.8% from a year earlier but net income plunged by 34.8% to €2.8 billion following a write-down of €3.6 billion largely due to weak sales of Eloctate, a product for haemophilia A. Eloctate and Alprolix, a product for haemophilia B, entered Sanofi’s portfolio in 2018 when it bought the Biogen Inc spin-out Bioverativ Inc. Both products are factor replacement therapies which are being challenged by new therapeutic modalities.
